An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.
about
Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?Pleiotropic effects of statinsHMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotectionStatins in heart failure: do we need another trial?Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspectiveHyperlipidemia, tissue factor, coagulation, and simvastatinReinforcing a continuum of care: in-hospital initiation of long-term secondary prevention following acute coronary syndromesPARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylationStatins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesionCoagulation dysregulation as a barrier to xenotransplantation in the primateAcute cholesterol depletion impairs functional expression of tissue factor in fibroblasts: modulation of tissue factor activity by membrane cholesterol.Macrophage roles following myocardial infarctionThe journey from stem cell to macrophage.Simvastatin re-couples dysfunctional endothelial nitric oxide synthase in experimental subarachnoid hemorrhageAliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects.Statins and cardiovascular diseases: from cholesterol lowering to pleiotropyThe effect of rosuvastatin in a murine model of influenza A infection.High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis.Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins.Nonlipid-lowering effects of statins.Lipoprotein(a) is associated with necrotic core progression of non-culprit coronary lesions in statin-treated patients with angina pectorisBasic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.Matrix metalloproteinases and atherosclerotic plaque instability.Lifestyle effects on hematopoiesis and atherosclerosis.Isoprenoids as mediators of the biological effects of statinsBicuspid aortic valve disease: the role of oxidative stress in Lrp5 bone formation.High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment.Early statin therapy for acute coronary syndromes.The role of matrix metalloproteinases in vascular disease.Stabilization of atherosclerotic plaques: new mechanisms and clinical targets.Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms.Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells.Effects of statin on circulating microRNAome and predicted function regulatory network in patients with unstable angina.Isoprenoid metabolism and the pleiotropic effects of statinsComparison of clinical outcomes of hydrophilic and lipophilic statins in patients with acute myocardial infarctionFibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata.Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis.Statin therapy reduces growth of abdominal aortic aneurysms.The cardioprotective effects of statins.Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
P2860
Q24630160-2318C895-2CA4-40BD-8ED8-0879103067BEQ24647863-9E6D7167-F879-44DF-84EE-3D911E18931DQ24793685-F9DD1FE9-152F-4839-9267-4E3081256206Q26998966-FC5E00FF-62B2-4597-9FEF-9F892839E211Q27002928-97AB330E-54AD-4DC9-B7E1-E6816F3E015EQ27024964-5C4BF988-1BC6-4C91-8D46-37893CA427A1Q28219559-B489C840-8FA8-4F00-B323-2FB4E09E9BE2Q28314913-4AEBA4A8-40C0-435C-9D7D-130AFA5EDE93Q30536352-4EB35528-38E0-49B2-89C3-E821C51DF140Q33381973-40686E9B-B99A-4A72-AA82-632CE2B79B8AQ33714176-9EEEC808-BDCF-4E0D-A913-F13880DE1568Q33802153-F533EC4D-5C80-48C8-8EEA-26DB216CA39DQ33817936-414D7C54-8FE1-43D3-AE03-742A311B1DD4Q33836890-321425C1-BEDD-4C38-B97A-DC0F87BE678BQ33893825-87C092B8-C5F6-42A1-85C9-976FF97F9648Q33960556-EB85C820-5800-4F8D-841D-44606BD017B2Q34247532-4680A3BB-95F7-4EDB-998E-9B36EA6448CFQ34412168-C8AC9047-CEE9-4CB4-85F2-A5600A52A226Q34429685-14ED1D77-070F-4F4A-9C63-DD8DF069F21FQ34466935-70EF6F34-9165-40DB-990B-373A1D5720C2Q34504402-3725B4B7-36E1-4BED-A084-1F4F4BB40035Q34618889-01CD361A-3B18-4D6F-8084-3AB3711DA625Q34655385-43EAEA95-78D8-4140-AD9B-EACA4DC5EB74Q34668164-27C5D9B0-2922-418F-BBE2-7B811CE1513EQ34774535-DE2D2548-B755-4524-9CD1-1B5FB5E81885Q34900192-10A630CE-651C-4848-B69B-DE80826D046BQ34973446-CACA1EF3-BE51-4099-85AC-C168E6DEEDB7Q34979669-DA610642-9646-470F-AE0C-875445D32B3AQ34981650-EF39405D-8776-4B34-9212-62F073EF7992Q34986368-3A7FBAA8-C94A-4F3E-85DC-A0463641B2DFQ35058227-674F7811-5A9E-433B-AC10-3A31B7E83A26Q35189302-77C42741-EC02-4D15-B180-7110DE6882AEQ35191515-91FBDC57-2497-47BA-A3A0-BE336E1168EBQ35197114-B7A44AE6-F7BF-4B93-A48F-0944140537D7Q35331615-C6F91B10-45CC-4814-AD0D-1736E3DFEE3CQ35492880-3845FC46-5263-40FF-8763-405799DCC2A5Q35553700-548D46B6-6FF6-4A0F-B85A-662038133E6EQ35560673-DEE33C34-F0E4-4FC5-BC44-4910631A2130Q35602770-8A6FF38A-5EDF-416D-8726-09D0F3CE097EQ35631260-D2ACEFB4-1036-4CC4-83F4-47EDBFDBF63F
P2860
An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
An HMG-CoA reductase inhibitor ...... e factor in vivo and in vitro.
@ast
An HMG-CoA reductase inhibitor ...... e factor in vivo and in vitro.
@en
type
label
An HMG-CoA reductase inhibitor ...... e factor in vivo and in vitro.
@ast
An HMG-CoA reductase inhibitor ...... e factor in vivo and in vitro.
@en
prefLabel
An HMG-CoA reductase inhibitor ...... e factor in vivo and in vitro.
@ast
An HMG-CoA reductase inhibitor ...... e factor in vivo and in vitro.
@en
P2093
P356
P1433
P1476
An HMG-CoA reductase inhibitor ...... e factor in vivo and in vitro.
@en
P2093
Fukumoto Y
Furukawa Y
Sugiyama S
P304
P356
10.1161/01.CIR.103.2.276
P407
P577
2001-01-01T00:00:00Z